Skip to content

Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome

Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02710084
Enrollment
18
Registered
2016-03-16
Start date
2016-04-29
Completion date
2020-07-29
Last updated
2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phelan-McDermid Syndrome

Brief summary

This is a pilot study examining the efficacy, safety and tolerability of intranasal oxytocin as a novel treatment in Phelan-McDermid syndrome (PMS). This study will utilize a randomized, placebo-controlled design for 12 weeks (phase 1), followed by an open-label extension for 12 weeks (phase 2). The purpose is to evaluate the effect of intranasal oxytocin on impairments in attention, social memory, socialization, language, and repetitive behaviors.

Interventions

DRUGOxytocin

Intranasal oxytocin

DRUGSaline

Placebo

Sponsors

Alexander Kolevzon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
5 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Have a diagnosis of Phelan-McDermid syndrome defined by pathogenic deletion or mutation of the SHANK3 gene and confirmed by chromosomal microarray or sequencing. * Must be between the ages of 5 and 17 * Must be on stable medication and psychosocial therapy regimens for at least three months prior to enrollment

Exclusion criteria

* Allergy to oxytocin * Active cardiovascular disease, epilepsy, or renal disease that is not controlled by medication * Pregnant, lactating or refuse to practice contraception if sexually active * Have caretakers who are unable to speak English, be consistently present at visits to report on symptoms, or are otherwise judged unable to comply with the protocol by the study team * Comorbid conditions such that the patient is too medically compromised to participate

Design outcomes

Primary

MeasureTime frameDescription
Change in Aberrant Behavior ChecklistBaseline and Week 12Change in scale at week 12 as compared to baseline. Aberrant Behavior Checklist - behavior rating subscales for the assessment of treatment effects.16 items, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score range from 0 to 48, with higher score indicating poorer health outcomes.

Secondary

MeasureTime frameDescription
Change in Visual Paired Comparison (VPC) TaskBaseline and Week 12Change in VPC Task has 2 subscores at week 12 as compared to baseline. The subject is initially presented with a target for familiarization and the familiar target is then paired with a novel target. Recognition is indexed by a novelty score derived from the percentage of time looking at the novel stimulus vs. the familiar stimulus. The Social-Novel Preference score refers to the proportion of time spent looking at novel stimuli out of all the time spent looking at both novel and familiar stimuli in the social test. The Nonsocial-Novel Preference score refers to the proportion of time spent looking at novel stimuli out of all the time spent looking at both novel and familiar stimuli in the nonsocial test.The scores are given in proportions with a range from -1 to 1. A score of -1 would mean the participant shows a preference for familiar stimuli and a score of 1 demonstrates a preference for novel stimuli.
Change in Gap-Overlap TaskBaseline and Week 12One of three computerized eye tracking tasks to measure attention. three computer screens are set up side by side. A stimulus initially appears on the central screen, and once the participant orients to that stimulus, another stimulus will appear on one of the lateral screens. In the gap condition, the central stimulus will disappear before the peripheral stimulus appears. In the overlap condition, the central stimulus will remain on the screen while the peripheral stimulus appears. In both conditions, reaction times of the participant's eye movements (saccadic reaction time) from the central stimulus to the peripheral stimulus will be measured. Gap Effect measures the difference between average Gap and Overlap saccade latencies.
Change in Flicker TasksBaseline and Week 12One of three computerized eye tracking tasks to measure attention. The flicker task, or the four-alternative forced-choice preferential looking paradigm - the time interval over which the visual system is able to parse information. Scores range from -1 to 1 with higher scores indicating better (more typical) performance.
Change in Vineland Adaptive Behavior ScalesBaseline and Week 12Mean change in scale at week 12 as compared to baseline. Vineland Adaptive Behavior Communication Domain measures adaptive functioning. Vineland-II subdomains (Communication, Daily Living Skills, Socialization, Motor, Adaptive Behavior Composite, Internalizing, Externalizing and maladaptive) are V-scale scores (M=15, SD=3). Higher scores indicate better developed adaptive social behavior. Vineland-II domain and composite values are standard scores (M=100, SD=15). Higher scores indicate better developed adaptive social behavior.
Change in Repetitive Behavior Scale-Revised (RBS-R)Baseline and Week 12Change in Repetitive Behavior Scale at week 12 as compared to baseline. the RBS-R is a 44-item self-report questionnaire consisting of subscales and one additional global rating score from 1-100. Score range for Stereotypic Behavior subscale is 0-27, Self-Injurious Behavior subscale is 0-24, Compulsive Behavior subscale is 0-18, Ritualistic/Sameness Behavior subscale is 0-36, and Restricted Interests subscale 0-9. Total scale for RBS-R is 0-214, with higher score indicating more severe problem.
Change in Clinical Global Impression - Severity ScalesBaseline and Week 12Mean Change in Clinical Global Impression-Severity Scales at week 12 as compared to baseline. Clinical Global Impressions (CGI) Rating Scales are commonly used to measure symptom severity and global improvement in treatment studies of patients with developmental disorders. There Severity Scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of illness at the time of assessment. Full scale from 1 - 7. Higher scores indicate greater symptom severity.
Change in Short Sensory Profile (SSP)Baseline and Week 12Mean Change in Short Sensory Profile Scale at week 12 as compared to baseline, measuring sensory sensitivity and sensory seeking behavior. The SSP is a 38-item caregiver questionnaire. Items are based on a 5-point Liker scale ranging from 1=always to 5=never. Tactile Sensitivity ranges from 7-35. Taste/Smell Sensitivity ranges from 4-20. Movement Sensitivity ranges from 3-15. Underresponsive/Seeks Sensation ranges from 7-35. Auditory Filtering ranges from 6-30. Low Energy/Weak ranges from 6-30. Visual/Auditory Sensitivity ranges from 5-25. Total scale range from 38-190. Lower scores indicate a higher probability of sensory processing abnormalities.
Change in Macarthur-Bates Communicative Development Inventory (MCDI)Baseline and Week 12Macarthur-Bates Communicative Development Inventory at week 12 as compared to baseline, measuring language. Words and Gestures Forms are for children ages 8-18 months. In the form, the first part prompts parents to document the child's understanding of hundreds of early vocabulary items separated into semantic categories such as animal names, household items, and action words. Parents mark the words understood or used, and the forms yield separate indexes of words understood and words produced. The second part of each form asks parents to record the communicative and symbolic gestures the child has tried or completed. Ranges for each subscale score are as follows: Phrases understood (0-28), Words understood (0-396), Words produced (0-396), Early gestures (0-18), Later gestures (0-45), Total gestures (0-63). Higher scores indicate a great number of words, phrases, or gestures understood or produced.
Change in EEG Tasks: Auditory HabituationBaseline and Week 12In the Auditory Habituation EEG task, participants listen to a series of 4 tones and the neural responses to each of these tones (event related potentials, ERPs ) are averaged. The N1 and P2 components are typical responses to auditory stimuli. The N1 response is the initial, quick response to hearing a stimulus, and P2 reflects the later processing of the stimulus. Both of these should be greater in response to the first tone, and then reduce in response to each subsequent tone. This is known as habituation, and is calculated as the change in Tone 1 minus Tone 2 response for both N1 and P2 components.
Number of Adverse Eventsweek 12Number of Adverse Events through week 12
Change in Caregiver Strain IndexBaseline and Week 12Mean Change Caregiver Strain Index at week 12 as compared to baseline. The Caregiver Strain Questionnaire is a 21-item measure of self-reported strain experienced by caregivers and families of youth with emotional problems, with responses on a 5-point Likert scale (0 = Not at all, 4 = very much). Full scale from 0 to 84, higher score indicates higher caregiver burden
Change in Mullen Scales of Early Learning (MSEL)baseline and 12 weeks.Change in Mullen Scales of Early Learning (MSEL) at week 12 as compared to baseline. The Mullen Scales results are reported using Age Equivalents, which provides an estimate of the chronological age (CA) in years and months at which a typically developing child demonstrates the skills displayed by the child being assessed. The Mullen Scales results are reported using T scores. (M = 100, SD = 15). Each subscale is standardized to calculate an age-equivalent score. Higher scores represent a higher CA, and therefore better outcome.

Countries

United States

Participant flow

Participants by arm

ArmCount
Saline Then Oxytocin
During the first phase, patients randomized to the placebo group received intranasal saline solution in doses of 24 IU two times daily, for a total of 48 IU. During the second phase of the study, all participants received intranasal oxytocin, in identical doses.
10
Intranasal Oxytocin
The first phase of the study followed a double-blind, placebo-controlled design. Participants randomized to the experimental group received intranasal oxytocin started the trial with a dose of 24 international units (IU) twice daily (BID), which was adjusted to 12 IU BID, subsequently the dose was increased to 24IU BID. Each insufflation delivered 4 IU and three insufflations (12 IU) in each nostril were given twice daily for a total daily dose of 48 IU. The second phase was a 12-week open-label extension phase during which all participants received intranasal oxytocin.
8
Total18

Withdrawals & dropouts

PeriodReasonFG000FG001
First Phase - 12 WeeksWithdrawal by Subject31

Baseline characteristics

CharacteristicTotalIntranasal OxytocinSaline Then Oxytocin
Aberrant Behavior Checklist Social Withdrawal (ABC-SW) subscale17.4 units on a scale
STANDARD_DEVIATION 5.9
14. units on a scale
STANDARD_DEVIATION 3.4
20.1 units on a scale
STANDARD_DEVIATION 6.1
Age, Continuous8.4 years
STANDARD_DEVIATION 3.2
6.8 years
STANDARD_DEVIATION 1.4
9.8 years
STANDARD_DEVIATION 3.6
Full Scale DQ21.4 T-score
STANDARD_DEVIATION 14.5
26.3 T-score
STANDARD_DEVIATION 16.7
17.4 T-score
STANDARD_DEVIATION 11.8
Nonverbal DQ22.7 T-score
STANDARD_DEVIATION 12.3
26.1 T-score
STANDARD_DEVIATION 13.1
20.1 T-score
STANDARD_DEVIATION 11.7
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
9 Participants4 Participants5 Participants
Sex: Female, Male
Male
9 Participants4 Participants5 Participants
Verbal DQ - developmental quotient20 T-score
STANDARD_DEVIATION 17.6
26.4 T-score
STANDARD_DEVIATION 21.3
14.9 T-score
STANDARD_DEVIATION 12.8

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1015 / 15
other
Total, other adverse events
9 / 1015 / 15
serious
Total, serious adverse events
0 / 100 / 15

Outcome results

Primary

Change in Aberrant Behavior Checklist

Change in scale at week 12 as compared to baseline. Aberrant Behavior Checklist - behavior rating subscales for the assessment of treatment effects.16 items, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score range from 0 to 48, with higher score indicating poorer health outcomes.

Time frame: Baseline and Week 12

Population: In the case of two participants who dropped out after week 4, difference scores were calculated for each outcome measure using the last observation carried forward (This is why some measures have N's of 9 and 7). Two participants dropped out after BL and were not included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
Saline Then OxytocinChange in Aberrant Behavior ChecklistIrritability-5 score on a scaleStandard Deviation 6.63
Saline Then OxytocinChange in Aberrant Behavior ChecklistHyperactivity-8.11 score on a scaleStandard Deviation 11.85
Saline Then OxytocinChange in Aberrant Behavior ChecklistStereotypy-2.22 score on a scaleStandard Deviation 4.66
Saline Then OxytocinChange in Aberrant Behavior ChecklistInappropriate speech-1.67 score on a scaleStandard Deviation 3.04
Saline Then OxytocinChange in Aberrant Behavior ChecklistSocial Withdrawal-7.44 score on a scaleStandard Deviation 4.58
Intranasal OxytocinChange in Aberrant Behavior ChecklistInappropriate speech-7.14 score on a scaleStandard Deviation 2.21
Intranasal OxytocinChange in Aberrant Behavior ChecklistSocial Withdrawal-2.42 score on a scaleStandard Deviation 3.15
Intranasal OxytocinChange in Aberrant Behavior ChecklistIrritability-1.71 score on a scaleStandard Deviation 7.13
Intranasal OxytocinChange in Aberrant Behavior ChecklistStereotypy0.57 score on a scaleStandard Deviation 2.99
Intranasal OxytocinChange in Aberrant Behavior ChecklistHyperactivity-2.71 score on a scaleStandard Deviation 7.34
Secondary

Change in Caregiver Strain Index

Mean Change Caregiver Strain Index at week 12 as compared to baseline. The Caregiver Strain Questionnaire is a 21-item measure of self-reported strain experienced by caregivers and families of youth with emotional problems, with responses on a 5-point Likert scale (0 = Not at all, 4 = very much). Full scale from 0 to 84, higher score indicates higher caregiver burden

Time frame: Baseline and Week 12

Population: incomplete form for one participant

ArmMeasureValue (MEAN)Dispersion
Saline Then OxytocinChange in Caregiver Strain Index-1.83 score on a scaleStandard Deviation 1.47
Intranasal OxytocinChange in Caregiver Strain Index-0.86 score on a scaleStandard Deviation 1.07
Secondary

Change in Clinical Global Impression - Severity Scales

Mean Change in Clinical Global Impression-Severity Scales at week 12 as compared to baseline. Clinical Global Impressions (CGI) Rating Scales are commonly used to measure symptom severity and global improvement in treatment studies of patients with developmental disorders. There Severity Scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of illness at the time of assessment. Full scale from 1 - 7. Higher scores indicate greater symptom severity.

Time frame: Baseline and Week 12

Population: Data from all participants who had data collected at 12 weeks.

ArmMeasureValue (MEAN)Dispersion
Saline Then OxytocinChange in Clinical Global Impression - Severity Scales-0.11 score on a scaleStandard Deviation 0.17
Intranasal OxytocinChange in Clinical Global Impression - Severity Scales-0.1 score on a scaleStandard Deviation 0.24
Secondary

Change in EEG Tasks: Auditory Habituation

In the Auditory Habituation EEG task, participants listen to a series of 4 tones and the neural responses to each of these tones (event related potentials, ERPs ) are averaged. The N1 and P2 components are typical responses to auditory stimuli. The N1 response is the initial, quick response to hearing a stimulus, and P2 reflects the later processing of the stimulus. Both of these should be greater in response to the first tone, and then reduce in response to each subsequent tone. This is known as habituation, and is calculated as the change in Tone 1 minus Tone 2 response for both N1 and P2 components.

Time frame: Baseline and Week 12

Population: Data results available only for those who underwent Auditory Habituation EEG task

ArmMeasureGroupValue (MEAN)Dispersion
Saline Then OxytocinChange in EEG Tasks: Auditory HabituationAuditory Habituation: P2 Habituation Change1.15 microvolts (µV)Standard Deviation 0.91
Saline Then OxytocinChange in EEG Tasks: Auditory HabituationAuditory Habituation: N1 Habituation Change0.05 microvolts (µV)Standard Deviation 0.37
Intranasal OxytocinChange in EEG Tasks: Auditory HabituationAuditory Habituation: N1 Habituation Change0.12 microvolts (µV)
Intranasal OxytocinChange in EEG Tasks: Auditory HabituationAuditory Habituation: P2 Habituation Change-3.48 microvolts (µV)
Secondary

Change in Flicker Tasks

One of three computerized eye tracking tasks to measure attention. The flicker task, or the four-alternative forced-choice preferential looking paradigm - the time interval over which the visual system is able to parse information. Scores range from -1 to 1 with higher scores indicating better (more typical) performance.

Time frame: Baseline and Week 12

Population: Only 1 participant with data from baseline and Week 12

ArmMeasureGroupValue (MEAN)
Intranasal OxytocinChange in Flicker TasksPreference for the Target Box at 0.2 Hz0.10 score on a scale
Intranasal OxytocinChange in Flicker TasksPreference for the Target Box at 0.5 Hz0.30 score on a scale
Intranasal OxytocinChange in Flicker TasksPreference for the Target Box at 1 Hz-0.12 score on a scale
Intranasal OxytocinChange in Flicker TasksPreference for the Target Box at 2 Hz0.03 score on a scale
Secondary

Change in Gap-Overlap Task

One of three computerized eye tracking tasks to measure attention. three computer screens are set up side by side. A stimulus initially appears on the central screen, and once the participant orients to that stimulus, another stimulus will appear on one of the lateral screens. In the gap condition, the central stimulus will disappear before the peripheral stimulus appears. In the overlap condition, the central stimulus will remain on the screen while the peripheral stimulus appears. In both conditions, reaction times of the participant's eye movements (saccadic reaction time) from the central stimulus to the peripheral stimulus will be measured. Gap Effect measures the difference between average Gap and Overlap saccade latencies.

Time frame: Baseline and Week 12

Population: Only 2 participants with data from both baseline and Week 12

ArmMeasureValue (MEAN)Dispersion
Saline Then OxytocinChange in Gap-Overlap Task63.81 milliseconds (ms)Standard Deviation 34.19
Secondary

Change in Macarthur-Bates Communicative Development Inventory (MCDI)

Macarthur-Bates Communicative Development Inventory at week 12 as compared to baseline, measuring language. Words and Gestures Forms are for children ages 8-18 months. In the form, the first part prompts parents to document the child's understanding of hundreds of early vocabulary items separated into semantic categories such as animal names, household items, and action words. Parents mark the words understood or used, and the forms yield separate indexes of words understood and words produced. The second part of each form asks parents to record the communicative and symbolic gestures the child has tried or completed. Ranges for each subscale score are as follows: Phrases understood (0-28), Words understood (0-396), Words produced (0-396), Early gestures (0-18), Later gestures (0-45), Total gestures (0-63). Higher scores indicate a great number of words, phrases, or gestures understood or produced.

Time frame: Baseline and Week 12

ArmMeasureGroupValue (MEAN)Dispersion
Saline Then OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Phrases understood0.83 score on a scaleStandard Deviation 6.62
Saline Then OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Words understood-9.17 score on a scaleStandard Deviation 52.59
Saline Then OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Words produced11.67 score on a scaleStandard Deviation 41.9
Saline Then OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Early gestures1.83 score on a scaleStandard Deviation 2.64
Saline Then OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Later gestures3 score on a scaleStandard Deviation 7.48
Saline Then OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Total gestures4.83 score on a scaleStandard Deviation 9.97
Intranasal OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Later gestures0.86 score on a scaleStandard Deviation 1.95
Intranasal OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Phrases understood1.43 score on a scaleStandard Deviation 3.55
Intranasal OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Early gestures0.29 score on a scaleStandard Deviation 1.38
Intranasal OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Words understood7 score on a scaleStandard Deviation 13.41
Intranasal OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Total gestures0.57 score on a scaleStandard Deviation 2.07
Intranasal OxytocinChange in Macarthur-Bates Communicative Development Inventory (MCDI)Words produced2.57 score on a scaleStandard Deviation 10.23
Secondary

Change in Mullen Scales of Early Learning (MSEL)

Change in Mullen Scales of Early Learning (MSEL) at week 12 as compared to baseline. The Mullen Scales results are reported using Age Equivalents, which provides an estimate of the chronological age (CA) in years and months at which a typically developing child demonstrates the skills displayed by the child being assessed. The Mullen Scales results are reported using T scores. (M = 100, SD = 15). Each subscale is standardized to calculate an age-equivalent score. Higher scores represent a higher CA, and therefore better outcome.

Time frame: baseline and 12 weeks.

ArmMeasureGroupValue (MEAN)Dispersion
Saline Then OxytocinChange in Mullen Scales of Early Learning (MSEL)Visual Reception0.29 T-scoreStandard Deviation 7
Saline Then OxytocinChange in Mullen Scales of Early Learning (MSEL)Receptive Language-1.86 T-scoreStandard Deviation 4.86
Saline Then OxytocinChange in Mullen Scales of Early Learning (MSEL)Fine Motor-0.29 T-scoreStandard Deviation 1.11
Saline Then OxytocinChange in Mullen Scales of Early Learning (MSEL)Expressive Language0.43 T-scoreStandard Deviation 2.61
Saline Then OxytocinChange in Mullen Scales of Early Learning (MSEL)Gross motor-1.57 T-scoreStandard Deviation 4.69
Intranasal OxytocinChange in Mullen Scales of Early Learning (MSEL)Expressive Language0.43 T-scoreStandard Deviation 1.8
Intranasal OxytocinChange in Mullen Scales of Early Learning (MSEL)Gross motor-0.86 T-scoreStandard Deviation 1.46
Intranasal OxytocinChange in Mullen Scales of Early Learning (MSEL)Visual Reception2.86 T-scoreStandard Deviation 3.3
Intranasal OxytocinChange in Mullen Scales of Early Learning (MSEL)Fine Motor0.71 T-scoreStandard Deviation 1.8
Intranasal OxytocinChange in Mullen Scales of Early Learning (MSEL)Receptive Language1.71 T-scoreStandard Deviation 2.7
Secondary

Change in Repetitive Behavior Scale-Revised (RBS-R)

Change in Repetitive Behavior Scale at week 12 as compared to baseline. the RBS-R is a 44-item self-report questionnaire consisting of subscales and one additional global rating score from 1-100. Score range for Stereotypic Behavior subscale is 0-27, Self-Injurious Behavior subscale is 0-24, Compulsive Behavior subscale is 0-18, Ritualistic/Sameness Behavior subscale is 0-36, and Restricted Interests subscale 0-9. Total scale for RBS-R is 0-214, with higher score indicating more severe problem.

Time frame: Baseline and Week 12

Population: Patients were only included in this analysis if they had RBS-R at BL and Week 12

ArmMeasureGroupValue (MEAN)Dispersion
Saline Then OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Compulsive behaviors-1.56 score on a scaleStandard Deviation 3.09
Saline Then OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Sameness behaviors-2 score on a scaleStandard Deviation 2.65
Saline Then OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Self-injury-1.22 score on a scaleStandard Deviation 3.11
Saline Then OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Restrictive behaviors-1.43 score on a scaleStandard Deviation 2.39
Saline Then OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Ritualistic behaviors-1.33 score on a scaleStandard Deviation 2.4
Saline Then OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Overall Score-8.56 score on a scaleStandard Deviation 13.29
Saline Then OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Stereotypic behaviors-1.67 score on a scaleStandard Deviation 2.78
Intranasal OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Overall Score0 score on a scaleStandard Deviation 5.56
Intranasal OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Stereotypic behaviors0.29 score on a scaleStandard Deviation 2.87
Intranasal OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Self-injury1 score on a scaleStandard Deviation 2.31
Intranasal OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Compulsive behaviors-0.14 score on a scaleStandard Deviation 0.69
Intranasal OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Ritualistic behaviors-0.43 score on a scaleStandard Deviation 1.62
Intranasal OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Sameness behaviors-0.29 score on a scaleStandard Deviation 1.6
Intranasal OxytocinChange in Repetitive Behavior Scale-Revised (RBS-R)Restrictive behaviors0.14 score on a scaleStandard Deviation 0.9
Secondary

Change in Short Sensory Profile (SSP)

Mean Change in Short Sensory Profile Scale at week 12 as compared to baseline, measuring sensory sensitivity and sensory seeking behavior. The SSP is a 38-item caregiver questionnaire. Items are based on a 5-point Liker scale ranging from 1=always to 5=never. Tactile Sensitivity ranges from 7-35. Taste/Smell Sensitivity ranges from 4-20. Movement Sensitivity ranges from 3-15. Underresponsive/Seeks Sensation ranges from 7-35. Auditory Filtering ranges from 6-30. Low Energy/Weak ranges from 6-30. Visual/Auditory Sensitivity ranges from 5-25. Total scale range from 38-190. Lower scores indicate a higher probability of sensory processing abnormalities.

Time frame: Baseline and Week 12

Population: In the case of two participants who dropped out after week 4, difference scores were calculated for each outcome measure using the last observation carried forward (This is why some measures have N's of 9 and 7). Two participants dropped out after BL and were not included in the analysis.

ArmMeasureGroupValue (MEAN)Dispersion
Saline Then OxytocinChange in Short Sensory Profile (SSP)Tactile2.56 score on a scaleStandard Deviation 5.17
Saline Then OxytocinChange in Short Sensory Profile (SSP)Auditory filtering4 score on a scaleStandard Deviation 5.68
Saline Then OxytocinChange in Short Sensory Profile (SSP)Movement-0.67 score on a scaleStandard Deviation 2
Saline Then OxytocinChange in Short Sensory Profile (SSP)Low energy/weak1.67 score on a scaleStandard Deviation 6.18
Saline Then OxytocinChange in Short Sensory Profile (SSP)Taste/Smell1.67 score on a scaleStandard Deviation 2.88
Saline Then OxytocinChange in Short Sensory Profile (SSP)Visual/auditory sensitivity1.89 score on a scaleStandard Deviation 2.57
Saline Then OxytocinChange in Short Sensory Profile (SSP)Summary total14.33 score on a scaleStandard Deviation 21.31
Saline Then OxytocinChange in Short Sensory Profile (SSP)Under-responsive/seeks attention4.44 score on a scaleStandard Deviation 5.5
Intranasal OxytocinChange in Short Sensory Profile (SSP)Summary total1 score on a scaleStandard Deviation 17.95
Intranasal OxytocinChange in Short Sensory Profile (SSP)Visual/auditory sensitivity-0.86 score on a scaleStandard Deviation 2.67
Intranasal OxytocinChange in Short Sensory Profile (SSP)Taste/Smell0.71 score on a scaleStandard Deviation 1.89
Intranasal OxytocinChange in Short Sensory Profile (SSP)Movement0.29 score on a scaleStandard Deviation 0.76
Intranasal OxytocinChange in Short Sensory Profile (SSP)Under-responsive/seeks attention0.71 score on a scaleStandard Deviation 4.68
Intranasal OxytocinChange in Short Sensory Profile (SSP)Auditory filtering0.29 score on a scaleStandard Deviation 5.21
Intranasal OxytocinChange in Short Sensory Profile (SSP)Low energy/weak-0.71 score on a scaleStandard Deviation 4.19
Intranasal OxytocinChange in Short Sensory Profile (SSP)Tactile1.57 score on a scaleStandard Deviation 3.78
Secondary

Change in Vineland Adaptive Behavior Scales

Mean change in scale at week 12 as compared to baseline. Vineland Adaptive Behavior Communication Domain measures adaptive functioning. Vineland-II subdomains (Communication, Daily Living Skills, Socialization, Motor, Adaptive Behavior Composite, Internalizing, Externalizing and maladaptive) are V-scale scores (M=15, SD=3). Higher scores indicate better developed adaptive social behavior. Vineland-II domain and composite values are standard scores (M=100, SD=15). Higher scores indicate better developed adaptive social behavior.

Time frame: Baseline and Week 12

Population: Participants were only included in this analysis if they had Vinelands at BL and Week 12. One incomplete Maladaptive subdomain form for one participant.

ArmMeasureGroupValue (MEAN)Dispersion
Saline Then OxytocinChange in Vineland Adaptive Behavior ScalesCommunication4 score on a scaleStandard Deviation 7.72
Saline Then OxytocinChange in Vineland Adaptive Behavior ScalesDaily Living Skills3.29 score on a scaleStandard Deviation 8.39
Saline Then OxytocinChange in Vineland Adaptive Behavior ScalesSocialization3 score on a scaleStandard Deviation 4.86
Saline Then OxytocinChange in Vineland Adaptive Behavior ScalesMotor1 score on a scaleStandard Deviation 3.46
Saline Then OxytocinChange in Vineland Adaptive Behavior ScalesAdaptive Behavior Composite3.14 score on a scaleStandard Deviation 3.8
Saline Then OxytocinChange in Vineland Adaptive Behavior ScalesInternalizing-1.14 score on a scaleStandard Deviation 1.07
Saline Then OxytocinChange in Vineland Adaptive Behavior ScalesExternalizing-1.14 score on a scaleStandard Deviation 2.73
Saline Then OxytocinChange in Vineland Adaptive Behavior ScalesMaladaptive-1.33 score on a scaleStandard Deviation 2.42
Intranasal OxytocinChange in Vineland Adaptive Behavior ScalesMaladaptive6 score on a scaleStandard Deviation 0.55
Intranasal OxytocinChange in Vineland Adaptive Behavior ScalesCommunication2.83 score on a scaleStandard Deviation 4.83
Intranasal OxytocinChange in Vineland Adaptive Behavior ScalesAdaptive Behavior Composite2 score on a scaleStandard Deviation 3.22
Intranasal OxytocinChange in Vineland Adaptive Behavior ScalesDaily Living Skills1.17 score on a scaleStandard Deviation 5.13
Intranasal OxytocinChange in Vineland Adaptive Behavior ScalesExternalizing6 score on a scaleStandard Deviation 1.33
Intranasal OxytocinChange in Vineland Adaptive Behavior ScalesSocialization-0.5 score on a scaleStandard Deviation 4.46
Intranasal OxytocinChange in Vineland Adaptive Behavior ScalesInternalizing6 score on a scaleStandard Deviation 0.84
Intranasal OxytocinChange in Vineland Adaptive Behavior ScalesMotor3.17 score on a scaleStandard Deviation 6.18
Secondary

Change in Visual Paired Comparison (VPC) Task

Change in VPC Task has 2 subscores at week 12 as compared to baseline. The subject is initially presented with a target for familiarization and the familiar target is then paired with a novel target. Recognition is indexed by a novelty score derived from the percentage of time looking at the novel stimulus vs. the familiar stimulus. The Social-Novel Preference score refers to the proportion of time spent looking at novel stimuli out of all the time spent looking at both novel and familiar stimuli in the social test. The Nonsocial-Novel Preference score refers to the proportion of time spent looking at novel stimuli out of all the time spent looking at both novel and familiar stimuli in the nonsocial test.The scores are given in proportions with a range from -1 to 1. A score of -1 would mean the participant shows a preference for familiar stimuli and a score of 1 demonstrates a preference for novel stimuli.

Time frame: Baseline and Week 12

Population: Only 3 participants with data from baseline and week 12

ArmMeasureGroupValue (MEAN)Dispersion
Saline Then OxytocinChange in Visual Paired Comparison (VPC) TaskSocial-Novel Preference0.01 score on a scale
Saline Then OxytocinChange in Visual Paired Comparison (VPC) TaskNonsocial-Novel Preference-0.38 score on a scale
Intranasal OxytocinChange in Visual Paired Comparison (VPC) TaskSocial-Novel Preference0.02 score on a scaleStandard Deviation 0.12
Intranasal OxytocinChange in Visual Paired Comparison (VPC) TaskNonsocial-Novel Preference0.22 score on a scaleStandard Deviation 0.12
Secondary

Number of Adverse Events

Number of Adverse Events through week 12

Time frame: week 12

ArmMeasureValue (NUMBER)
Saline Then OxytocinNumber of Adverse Events41 events
Intranasal OxytocinNumber of Adverse Events35 events

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026